The ICH M11 guideline, adopted in November 2025, and CDISC's USDM v4.0 represent two complementary efforts to standardize how clinical trial protocols are structured and shared. M11 defines a common protocol template and technical specification so protocols from different sponsors use consistent structure and terminology. USDM models study design elements as structured data rather than prose, enabling machines to read and act on protocol content. The potential payoff is narrower than many assume: these standards do not eliminate the regulatory or strategic reasons protocols get amended, but they may reduce the manual reconciliation work required when an approved change needs to propagate to downstream systems like EDC, IRT, and registry entries. A 2024 analysis found 76% of protocols now carry at least one substantial amendment, up from 57% in 2016, with median Phase III amendment costs reaching $535,000. Neither standard is mandatory. FDA permits alternative approaches, and USDM v4.0 was released before the final M11 text, leaving gaps CDISC plans to close in a v4.1 release targeted for late 2026. For sites, the immediate impact is limited, but sponsors adopting these standards may eventually deliver more consistent protocol documents and faster amendment turnaround times, provided the underlying system integrations are built and validated first.